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Abstract
We conducted a preoperative window study of metformin in endometrial can-
cer (EC) patients and evaluated its antiproliferative, molecular and metabolic
effects. Twenty obese women with endometrioid EC were treated with metfor-
min (850 mg) daily for up to 4 weeks prior to surgical staging. Expression of
the proliferation marker Ki-67, estrogen receptor (ER), progesterone receptor
(PR), adenosine monophosphate-activated protein kinase (AMPK), and down-
stream targets of the mammalian target of rapamycin (mTOR) pathway were
measured by immunohistochemistry. Global, untargeted metabolomics analysis
of serum pre- and postmetformin treatment, and matched tumor, was per-
formed. Metformin reduced proliferation by 11.75% (P = 0.008) based on the
comparison of pre- and posttreatment endometrial tumors. A total of 65% of
patients responded to metformin as defined by a decrease in Ki-67 staining in
their endometrial tumors post-treatment. Metformin decreased expression of
phosphorylated (p)-AMPK (P = 0.00001), p-Akt (P = 0.0002), p-S6 (51.2%,
P = 0.0002), p-4E-BP-1 (P = 0.001), and ER (P = 0.0002) but not PR expres-
sion. Metabolomic profiling of serum indicated that responders versus nonre-
sponders to treatment were more sensitive to metformin’s effects on induction
of lipolysis, which correlated with increased fatty acid oxidation and glycogen
metabolism in matched tumors. In conclusion, metformin reduced tumor pro-
liferation in a pre-operative window study in obese EC patients, with dramatic
effects on inhibition of the mTOR pathway. Metformin induced a shift in lipid
and glycogen metabolism that was more pronounced in the serum and tumors
of responders versus nonresponders to treatment.This study provides support
for therapeutic clinical trials of metformin in obese patients with EC.
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The American Cancer Society estimates that nearly 50,000
new cases of endometrial carcinoma will be diagnosed in
2014 [1]. Obesity, diabetes, and insulin resistance are
well-known risk factors that drive the development of
endometrial cancer [2, 3]. Unfortunately, obesity is not
only a risk factor for endometrial cancer, but also may be
associated with an increased risk of death from this dis-
ease [4]. Specifically, an association with all-cause mortal-
ity in endometrial cancer as a function of body mass has
been found, with obese patients having a relative risk of
death 2.5 times higher than their nonobese counterparts
and morbid obesity carrying a relative risk of over six
times that of patients with a normal body mass index
(BMI) [5]. Obesity is an epidemic in the United States
and worldwide, with over 65% of the US population
being overweight and 33% obese [6]. The severity of obes-
ity-associated endometrial cancer suggests that tumors
arising in the obese state may display altered tumor biol-
ogy (or changes in the microenvironment) that drive car-
cinogenesis, providing a unique opportunity to inhibit
obesity-activated pathways as a therapeutic strategy.
Metformin is an antidiabetic medication from the bigu-
anide class that is widely used as the first line treatment
of type 2 diabetes. Epidemiological evidence suggests that
metformin use lowers cancer risk and reduces cancer
deaths among diabetic patients [7–10], including those
with endometrial cancer [11–13]. Metformin is believed
to have both indirect and direct effects on tumor growth
[7, 8], and it is unknown which of these effects are most
important for metformin’s antitumorigenic benefits. Its
indirect effects are likely to be due to inhibition of hepa-
tic gluconeogenesis, resulting in an improvement in insu-
lin sensitivity and a reduction of blood glucose and
circulating insulin levels, which may lead to decreased
growth factor-stimulated tumor growth [7, 8]. On a
direct level, metformin may affect tumor growth by acti-
vation of adenosine monophosphate-activated protein
kinase (AMPK), its intracellular target for antidiabetic
effects, which leads to the regulation of multiple down-
stream signaling pathways that control cellular prolifera-
tion, including inhibition of the mammalian target of
rapamycin (mTOR) pathway [7, 8]. Alterations in the
mTOR pathway, including inactivating PTEN mutations
and PIK3CA amplifications or activating mutations, are
common in endometrial cancers [14, 15]. Consistent with
these observations, our pre-clinical studies reveal that
metformin inhibits cell proliferation in endometrial can-
cer cell lines through inhibition of mTOR signaling, and
behaves as a chemosensitizer when combined with
cytotoxic agents [16, 17]. Preoperative window studies
of metformin in patients planning to undergo surgical
resection of breast cancer have shown promising results
in metformin’s ability to reduce proliferation indices (i.e.,
Ki-67) and increase apoptosis [18–20]. It is likely that
women with endometrial cancer may also benefit from
metformin’s antiproliferative effects, especially in obese
patients who may have elevated circulating insulin and
glucose levels as well as activation of the mTOR pathway
in their endometrial tumors. Thus, we conducted a pre-
operative window clinical trial of metformin in obese
women with endometrial cancer to evaluate short-term
effects on cell proliferation and assess potential molecular
and metabolic biomarkers of treatment response.
Materials and Methods
Study design
After obtaining approval from the University of North
Carolina at Chapel Hill (UNC-CH) Institutional Review
Board (IRB# 11-0575), a prospective, open label, preoper-
ative window study was conducted to evaluate the effects
of metformin on the endometrium in obese women with
endometrial cancer. The inclusion criteria for enrollment
in this study were that patients had to have tumors of
endometrioid histology, were between the ages of
18–75 years, and were obese with a BMI ≥30. Surgical
intervention was required within 7–28 days of enrollment.
Patients were excluded if they were diabetics on metfor-
min or insulin (currently or in the past 6 months), had
an elevated creatinine (>1.0) or AST/ALT (>38 or >48,
respectively), had a history of alcoholism or B12 defi-
ciency, were pregnant, had hormonal intervention within
4 weeks of evaluation, or had any other contraindications
to metformin therapy.
The trial and participant flow diagram is described in
Figure 1A. Patient charts for all women presenting to the
gynecologic oncology clinic at UNC-CH with a new diag-
nosis of endometrioid endometrial cancer were screened.
Patients meeting these inclusion criteria were offered to
participate in the study. If they wished to proceed,
informed consent was obtained. Height and weight were
recorded, and BMI was calculated. Laboratory evaluation,
including creatinine, AST/ALT, and HgbA1c values, was
obtained prior to metformin treatment. Once these values
returned within treatment parameters, patients were
started on metformin 850 mg orally daily. The research
nurse for this study contacted the patients weekly after
trial initiation to assess toxicity, using the definitions and
criteria for grading provided in the NCI Common
Toxicity Criteria for Adverse Events (CTCAE), version
4.0. Patients stopped metformin 24 h prior to surgery, as
a means to decrease the rare but serious risk of lactic aci-
dosis. Serum was collected and stored at 80°C pre- and
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post metformin treatment for metabolomic profiling.
Patients were not fasting at the time the pretreatment
serum specimens were collected. Patients were fasting at
the time the posttreatment serum specimens were col-
lected, given that these samples were collected at the time
of hysterectomy and surgical staging. Since all patients
fasted at the time of post-treatment collection of samples,
differences observed between responders and nonrespond-
ers to metformin treated should not be affected by the
fasting state. Fresh endometrial tumors were collected
postmetformin treatment and snap frozen in liquid nitro-
gen for metabolomic profiling. Formalin-fixed, paraffin-
embedded endometrial tumors from premetformin treat-
ment endometrial biopsies and postmetformin treatment
hysterectomy specimens were collected for immunohisto-
chemical analysis. Pathologic characteristics of the endo-
metrial tumors were obtained from pathology reports,
including stage, grade, histology, and nodal status.
Immunohistochemical analysis
Triplicate cores were made of endometrial tumors pre-
(endometrial biopsy) and postmetformin treatment
(hysterectomy), and tissue microarrays were created.
Immunohistochemical analysis was performed on 4-lmol/
L sections of formalin-fixed, paraffin-embedded tissues
using standard methodologies. The primary antibodies
included the following: (1) anti-Ki-67 monoclonal anti-
body, M7240, Dako (Carpinteria, CA), (2) antiestrogen
receptor (ER) monoclonal antibody, 249R-16, Cell Marque
(Rocklin, CA), (3) antiprogesterone receptor (PR) mono-
clonal antibody, 323R-16, Cell Marque (4) antiphosphory-
lated AMPKa monoclonal antibody, 2535, Cell Signaling
Technology (Danvers, MA), (5) antiphosphorylated Akt
(ser 473) monoclonal antibody, 4060, Cell Signaling Tech-
nology, (6) antiphosphorylated S6 ribosomal protein
monoclonal antibody, 4858, Cell Signaling Technology,
and (7) antiphosphorylated 4E-BP-1 monoclonal anti-
body, 2855, Cell Signaling Technology. Negative controls
(lacking primary antibody) were performed for each anti-
body. Individual slides were scanned using the AperioTM
ScanScope (Aperio Technologies, Vista, CA), and digital
images were analyzed using AperioTM ImageScope software.
This work was performed with the assistance of the
UNC-CH Translational Pathology Laboratory (TPL) Core.
Metabolomic profiling
Metabolomic profiling was performed on serum obtained
from patients pre- and postmetformin treatment as well
as on endometrial tumors obtained post-treatment at sur-
gery. Samples were analyzed by Metabolon (Research Tri-
angle Park, NC) according to their standard protocols
[21–24]. Briefly, unbiased global metabolomic profiling
was achieved using methanol extracts of serum or tumor





Figure 1. (A) Participant and trial flow diagram. (B) Metformin inhibited cellular proliferation in endometrial cancer patients. Obese endometrial
cancer patients (n = 20) underwent short-term metformin treatment (mean of 14.65 days) in a preoperative window study. Percent Ki-67
staining, a marker of cellular proliferation, decreased significantly with metformin treatment (overall mean decrease of 11.75%, P = 0.008; mean
decrease of 21.9% among responders to metformin.). Representative images are shown from pretreatment endometrium and posttreatment
endometrium in a patient that responded to metformin treatment as demonstrated by a decrease in Ki-67 immunohistochemical staining.
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Analysis of extracts consisted of either ultrahigh perfor-
mance liquid chromatography (Waters Corporation,
Milford, MA) coupled with tandem mass spectrometry
(UHPLC/MS/MS; Thermo-Finnigan, San Jose CA) in
positive and negative ionization modes, or via gas chro-
matography/MS analysis (Thermo-Finnigan). Metabolites
in serum or tumor tissues were positively identified by
matching chromatographic retention time, mass, and
MS/MS fragmentation patterns to a reference library of
over 2500 purified, authenticated biochemicals. Data are
presented as relative measures of “scaled intensity” and
median scaling to 1. Missing values were imputed with
the minimum.
Statistical analysis
The signed-rank test was used to evaluate the difference
between pre- and posttreatment Ki-67, ER, PR, phosphor-
ylated AMPK, phosphorylated Akt, phosphorylated S6,
and phosphorylated 4E-BP-1immunohistochemical stain-
ing. Responders to metformin treatment were defined as
those patients with an absolute reduction in %Ki-67
staining. Nonresponders were defined as those who had
an increase in %Ki-67 staining. Demographics were com-
pared between responders and nonresponders to metfor-
min treatment, using the Student’s t-test. Significance was
defined at P < 0.05.
For the metabolomic profiling, two types of statistical
analyses were performed: (1) significance tests and (2) clas-
sification analysis. For pairwise comparisons, Welch’s t-
tests and/or Wilcoxon’s rank sum tests were performed.
Where appropriate, repeated measures analysis of variance
(ANOVA) were used. For classification analysis, random
forest analyses were performed. Random forest is a super-
vised classification technique based on an ensemble of deci-
sion trees [25]. For a given decision tree, a random subset
of the data with identifying true class information is
selected to build the tree (“bootstrap sample” or “training
set”), and then the remaining data, the “out-of-bag”
(OOB) variables, are passed down the tree to obtain a class
prediction for each sample. This process is repeated thou-
sands of times to produce the forest. The final classification
of each sample is determined by computing the class pre-
diction frequency (“votes”) for the OOB variables over the




Pre- and postmetformin endometrial tumor specimens
were obtained from 20 obese women with endometrial
cancer (Fig. 1A). The mean age was 58.8 years, and the
mean pre-metformin treatment BMI was 39.6 kg/m2
(range 30.8–52.2 kg/m2). Patients received metformin for
a mean duration of 14.6 days (range of 7–28 days) prior
to surgical resection of the uterus. All patients had stage 1
or 2 disease, and 85% of the endometrial cancer tumors
were either grade 1 or 2. Three patients experienced grade
1gastrointestinal toxicities while taking metformin,
including abdominal pain, loose stools, and flatulence.
These were all self-limited and did not require discontin-
uation of study drug. There was no grade 2 or higher
toxicities among our study population, as defined by the
NCI Common Toxicity Criteria for Adverse Events
(CTCAE), version 4.0. Glucose levels decreased in
responders and nonresponders to metformin but were
only statistically significant in responders (P = 0.007).
Metformin treatment prior to surgery
reduced proliferation of endometrial
tumors
Metformin significantly reduced Ki-67 staining by 11.75%
in endometrial tumors, when comparing posttreatment
hysterectomy specimens to pretreatment endometrial
biopsies (P = 0.008) (Fig. 1B). Responders to metformin
treatment were defined as those patients with an absolute
decrease in %Ki-67 staining (decrease range of 7–50%).
Nonresponders were defined as those who had an increase
in %Ki-67 staining (increase range of 2–12%). Overall,
65% of patients (13/20) responded to metformin treat-
ment, with a mean decrease in Ki-67 staining of 21.9%
among responders to metformin. No significant differ-
ences were detected in clinical factors (including age,
premetformin treatment BMI, premetformin treatment
HgbA1c, grade, stage, toxicity or number of days on
treatment) between responders and nonresponders to
metformin treatment (Table 1). Pretreatment Ki-67 indi-
ces were statistically higher in women who responded to
metformin treatment (47.3% vs. 24.9%, P = 0.004).
Metformin blunted mTOR signaling in
tumors
Metformin significantly decreased phosphorylation of
downstream targets of the mTOR pathway and impacted
hormonal receptor expression in posttreatment hysterec-
tomy specimens versus pretreatment endometrial biopsies.
Metformin decreased expression of phosphorylated (p)-
AMPK (60.3%, P = 0.00001), p-Akt (44.2%, P = 0.0002),
p-S6 (51.2%, P = 0.0002), and p-4E-BP-1 (74.7%,
P = 0.001) (Fig. 2). ER expression was also decreased
after treatment with metformin (65.7%, P = 0.0002);
however, there was no effect on PR expression (P = 0.28).
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Pretreatment expression of ER, PR, p-AMPK, p-Akt, p-S6
or p-4E-BP-1 did not predict response to metformin ther-
apy.
Metabolic markers of respone to metformin
treatment
We sought to determine the biochemical impact of met-
formin on patients with endometrial cancer by analyzing
serum metabolomic profile changes from baseline to post-
metformin therapy, specifically comparing responders ver-
sus nonresponders to metformin treatment. Serum was
collected pre- and postmetformin treatment on 12/13
responders to metformin treatment and 6/7 nonrespond-
ers to metformin. Tumors were isolated for pathology
and patient care, and the majority was available for meta-
bolomics analysis. Postmetformin tumors were obtained
from 9/13 responders and 3/7 nonresponders.
Metformin treatment significantly altered the serum
concentrations of 173 metabolites (37 up and 136 down)
(Table S1). Comparison of global biochemical profiles
from serum and tumors revealed several key metabolic
differences between responders and nonresponders to
metformin treatment. In serum, 114 significant metabo-
lites in responders and 67 metabolites in nonresponders
were altered when compared to their respective premet-
formin treatment measures (Table S1). Although serum
metformin appeared to be more elevated in the responder
group than the nonresponder group posttreatment, a
single outlier within the responder group drove this seem-
ing difference that did not reach statistical significance
(P = 0.7849). The observed difference in serum metfor-
min between the two posttreatment groups is also likely
complicated by levels of metformin approaching the limit
of detection of the metabolomic platform in the fasted
posttreatment groups, as metformin has been reported to
be undetectable in human plasma by 24 h post-dose [26].
Lidocaine showed the lowest P-value when comparing
posttreatment groups versus pretreatment groups (Table
S1), which is consistent with no lidocaine being detected
in any pretreatment group sample and the perisurgi-
cal timing of the posttreatment sampling. Supervised
classification showed a limited effect of metformin on
Table 1. Demographic information among responders and nonre-





(N = 7) P-value
Age (years) 60 (9.6) 60 (9.6) NS
BMI 38.4 (5.4) 41.8 (7.2) NS
HgbA1c 5.6 (0.4) 5.6 (0.5) NS
Duration of metformin
treatment (days)
13.1 (5.3) 17.4 (7.7) NS
Grade 1 AEs 1 2 NS
Grade 2-4 AEs 0 0 NS
Stage
1A 8 7 NS
1B 4 0 NS
2 1 0 NS
Grade
1 8 2 NS
2 4 3 NS
3 1 2 NS








Figure 2. Metformin decreased expression of phosphorylated-Akt
(P = 0.0002), phosphorylated-AMPK (P = 0.00001), phosphorylated-S6
(P = 0.0002),s and phosphorylated-4E-BP-1 staining (P = 0.001). (A)
Phosphorylated-Akt staining premetformin treatment. (B) Phos-
phorylated-Akt staining postmetformin treatment. (C) Phosphory-
lated-AMPK staining premetformin treatment. (D) Phosphorylated-
AMPK staining postmetformin treatment. (E) Phosphorylated-S6
staining premetformin treatment. (F) Phosphorylated-S6 staining post-
metformin treatment. (G) Phosphorylated-4E-BP-1 staining premetformin
treatment. (H) Phosphorylated-4E-BP-1staining postmetformin treatment.
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nonresponder patients versus their respective baseline
profiles, with a predictive accuracy of 67% by Random
Forest analysis. In contrast, supervised classification dem-
onstrated a predictive accuracy of 91% when comparing
responders to their respective baseline profiles. The top
thirty biochemicals that drove the ability to accurately
classify samples from responders versus nonresponders
are shown in Figure 3. Metabolic alterations driven by
metformin in the responders primarily related to elevated
lipid metabolism, more efficient amino acid metabolism,
increased xenobiotic presence, and altered gut microbi-
ome-associated metabolites.
When comparing posttreatment to pretreatment serum,
the greatest changes were seen in regard to lipid metabo-
lism (Fig. 4), with more significant effects observed in
responders versus nonresponders to metformin treatment.
Lipid metabolites increased by metformin treatment
included ketone bodies, such as acetoacetate and
3-hydroxybutyrate, long chain fatty acids such as palmi-
toleate, 10-heptadecenoate, oleate, stearate, nonadecano-
ate, and eicosenoate as well as elevated glycerol levels
(P < 0.05, Fig. 4 and Table S2).
Metabolomic analysis of endometrial tumors after met-
formin treatment demonstrated significant differences in
lipid metabolism in responders versus nonresponders
(Fig. 5). Fourteen metabolites related to lipid metabolism
were found to be affected by metformin treatment,
including polyunsaturated fatty acids and the ketone
body, 3-hydroxybutyrate. Metformin was found to have
differential effects in the endometrial tumors of respond-
ers versus nonresponders to treatment (Fig. 5A, Table
S2). In particular, docosatrienoate, linolenate, and diho-
mo-linolenate levels were lower in the endometrial
tumors of responders versus nonresponders (P < 0.05).
However, classification predictive accuracy was only 33%
in separating endometrial tumors of responders versus
nonresponders to metformin.
Glycogen synthesis was also significantly altered by
metformin treatment in endometrial tumors. Glucose was
elevated in the endometrial tumors isolated from
responders as compared to nonresponders to metformin,
although this was not statistically significant (Table S3).
Elevated tumor glucose in the responder samples was
concomitant with significantly elevated levels of several
glycogen metabolites, including maltopentaose and malt-
ose (P < 0.05) (Fig. 5B), while maltotetraose was elevated
but not statistically significant (Fig. 5B).
Discussion
In a preoperative window study in obese, nondiabetic
endometrial cancer patients, we demonstrate that metfor-
min significantly decreased proliferation in the malignant
endometrium, with parallel effects on inhibition of the
mTOR pathway. The majority of patients (65%)





Figure 3. Random forest analysis of post-metformin treatment (Post-Tx) vs. premetformin treatment (Pre-Tx) serum samples from endometrial
cancer patients. Random Forest classification using named metabolites in serum of Post-Tx compared to Pre-Tx sample gave an overall predictive
accuracy of 97%, with a predictive accuracy of 91% for responders to metformin treatment versus only 67% for nonresponders to treatment.
These changes were mainly related to alterations in lipid metabolism, amino acid, xenobiotic presence, and gut microbial-associated metabolites.
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reduction in Ki-67 staining. Higher expression of baseline
Ki-67 staining was a predictor of response to metformin
therapy, suggesting that rapidly proliferating tumors
responded best to this agent. Metformin was well-toler-
ated among the endometrial cancer patients enrolled, with
no patients discontinuing treatment due to toxicities.
Glucose levels decreased in responders and nonresponders
to metformin but were only statistically significant in
responders.
Differential effects of metformin were found in the
serum of patients whose endometrial tumors responded
favorably to drug exposure when compared to those who
did not respond, as demonstrated by metabolomic profil-
ing. The major overall biochemical response of patients to
metformin treatment was related to lipid metabolism,
with more significant effects seen in the serum of
responders versus nonresponders to treatment. Lipid
metabolites increased by metformin treatment included
ketone bodies, long chain fatty acids, and glycerol. The
most profound change in metabolite concentration in
response to metformin was 3-hydroxybutyrate, a marker
of mitochondrial fatty acid b-oxidation, which was signif-
icantly elevated in both responder and nonresponder
groups. Elevations of free fatty acids and glycerol in the
serum, most likely released primarily from adipose tissue,
indicate that metformin-associated lipolysis was more
pronounced in the responders versus nonresponders. The
impact of metformin on lipolysis remains controversial
with some studies reporting inhibition of lipolysis
[27–31] and others reporting stimulation of lipolysis with
metformin treatment in adipose tissue [32]. Differences
among these studies may be related to duration of treat-
ment with metformin and method of detection of lipoly-
sis and free fatty acids. Regardless, data presented herein
suggest that endometrial cancer patients who responded
to metformin were particularly sensitive to its metabolic
effects on lipid metabolism, supporting the critical role of
the indirect effects of metformin in endometrial cancer
treatment. Of note, metformin was stopped 24 h prior
surgery for safety reasons, i.e., minimizing the risk of lac-
tic acidosis that could result from the stress of surgery.
This may have some impact on the metabolomic profiling
results; however, we would expect that the overall meta-
bolic effects of metformin to persist beyond the 24 h of it
being stopped prior to surgery.
Metabolic responses in the endometrial tumors of
responders as compared to nonresponders to metformin
treatment were coincident with metabolic changes in the
serum. Despite the small sample size of endometrial
tumors available for metabolomic analysis and the low
predictive power in separating tumors from responders
versus nonresponders (33%), 14 metabolites were identi-
fied that were differentially regulated by metformin
response, including polyunsaturated fatty acids and the
ketone body, 3-hydroxybutyrate. Lower free fatty acids












Figure 4. Lipid metabolism was altered in both responders and nonresponders to metformin treatment, but more pronounced effects were seen
in the serum/ of responders. (A) Cartoon of triacylglyceride hydrolysis, b-oxidation, and tricarboxylic acid cycle (TCA cycle). (B) 3-hydroxybutyrate
(BHBA), a marker of mitochondrial fatty acid b-oxidation, was elevated in both responders (Res) and nonresponders (Non-Res), but palmitoleate
and glycerol were much more increased in responders to metformin treatment (*P < 0.05).
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fatty acid oxidation in tumors of responders to metfor-
min treatment, which could also contribute to the appar-
ent release of free fatty acids found in the serum. In
addition, the most notable impact on lipid metabolites
was with n3 and n6 fatty acids, which are known to serve
as substrates for cyclooxygenase (COX)-mediated eicosa-
noid biosynthesis, which may indicate differential effects
of metformin on tumor COX activity between responders
and nonresponders to treatment.
Increased glycogen synthesis, as evidenced by a signifi-
cant accumulation of several glycogen metabolites, was
found in the tumors of responders versus nonresponders
to metformin treatment. Energetically, this shift in glucose
metabolism toward glycogen synthesis may result in
diminished glucose availability to tumor cells. While in
vitro studies have reported inhibition of glycogen synthe-
sis in hepatocytes and myotubes [33, 34], the acute
concentrations of metformin that cells were exposed to in
these studies were well above pharmacological relevance
(200 lmol/L–10 mmol/L vs. 10–20 lmol/L reported
pharmacologic concentrations) [35]. In vivo studies, how-
ever, show that metformin treatment or chronic activa-
tion of AMPK via repeat dosing of rats with the
adenosine analog 5-aminoimidazole-4-carboxamide ribo-
nucleoside (AICAR) leads to glycogen accumulation in
liver and muscle [36, 37]. Hence, the metabolomic profile
of increased glycogen synthesis observed in endometrial
tumors reported herein likely relates to dose- and dura-
tion-specific responses of endometrial tumors to metfor-
min in vivo, when compared to in vitro exposure
scenarios. Interestingly, lactate was not elevated in the
tumor cells following metformin exposure, suggesting that
metformin was not enhancing Warburg glycolytic metab-




















Figure 5. Metabolic changes in the endometrial tumors of responders as compared to nonresponders to metformin treatment were coincident
with metabolic changes in the serum. (A) Several lipid metabolites, including docosatrienoate and linolenate, were decreased in the endometrial
tumors of responders versus nonresponders to metformin treatment (P < 0.05). BHBA, a marker of mitochondrial fatty acid b-oxidation, was
elevated in responder tissues but did not reach statistical significance (P = NS). (B) Increased glycogen synthesis was demonstrated in the tumors
of responders as compared to nonresponders to metformin treatment. Glucose can be used for energy production through glycolysis or for
storage through glycogen synthesis. Glycogen metabolites, maltopentaose (P < 0.05), maltotetraose (P = NS), and maltose (P < 0.05),
accumulated in responders to metformin. *P < 0.05.
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within the tumor to storage as glycogen. Overall, systemic
metabolic changes related to metformin treatment and
response correlated to similar changes in the endometrial
tumors themselves, signifying the interrelationship
between the indirect and direct antitumor effects of met-
formin. In Figure 6, we summarize the indirect and direct
effects seen by meforminin in this preoperative window
study, including a decrease in serum glucose and
enhanced lipolysis coupled with inhibition of the mTOR
pathway and increased fatty acid oxidation and glycogen
synthesis in the endometrial tumor cells themselves. Of
course, we do acknowledge that this study is limited by
its small sample size, and our results need further valida-
tion in larger scale trials of metformin for endometrial
cancer treatment. In addition, to further delineate the
interaction between the metabolic and anticancer effects
of metformin demonstrated in this clinical trial, parallel
studies of metformin are underway in obese and nonob-
ese endometrial cancer mouse models.
To date, three preoperative window trials of metformin
in breast cancer patients have been conducted with mixed
results. Of these studies, one was a single arm study, one
was a randomized control trial of metformin versus no
treatment, and one was a randomized controlled trial of
metformin versus placebo. Two of these trials resulted in
a statistically significant lowering of the Ki-67 index [18,
19]. BMI, weight and homeostasis model assessment
(HOMA) scores also decreased significantly with short-
term metformin treatment in the study by Niraula et al.
[19]. Transcriptome profiling of breast tumors pre- and
postmetformin treatment found that metformin downreg-
ulated phosphodiesterase 3B, a critical regulator of cAMP
levels that also regulates activation of AMPK [18]. Met-
formin was also found to have significant effects on the
tumor necrosis factor receptor-1, mTOR, AMPK, p53,
BRCA1, and cell cycle pathways [18].
In the third and largest preoperative window study of
metformin in breast cancer patients, Bonanni et al., ran-
domized 200 women to metformin or placebo in a 1:1
ratio [25]. This study failed to reach its primary objective
in reducing Ki-67 indices in postresection breast cancers
[20]. However, women with higher BMIs and HOMA
indices had a significant response to metformin as evi-
denced by a decrease in Ki-67 staining [20]. These
findings suggest that the antitumorigenic effects of met-
formin may be more related to its ability to improve the
metabolic milieu of patients as opposed to a direct action
on tumor cells. Preclinical data in animal models also
suggests that the antitumorigenic efficacy of metformin
may be dependent on the metabolic composition of its
host. Metformin has been found to be more effective in
inhibiting tumor growth in obese and insulin resistant
animals versus their lean counterparts in breast and lung
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Figure 6. Indirect and direct effects seen by meformin in a preoperative window study in obese endometrial cancer patients. Metformin
treatment resulted in a systemic decrease in serum glucose and enhanced lipolysis coupled with inhibition of the mTOR pathway and increased
fatty acid oxidation and glycogen synthesis in the endometrial tumor cells themselves. These effects were more pronounced in responders versus
nonresponders to metformin treatment.
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beneficial in those patients who are obese with insulin
resistance, and further studies are warranted to determine
whether the extent of obesity and the metabolic composi-
tion of the host may play a role in metformin’s antitu-
morigenic effects.
There have been two other reported preoperative
window studies of metformin in newly diagnosed endo-
metrial cancer patients [40, 41]. As with the data pre-
sented here, endometrial cancer patients in both of these
studies were treated with short-term metformin prior to
hysterectomy and surgical staging [40, 41]. One of these
studies demonstrated reduced Ki-67 staining in endome-
trial tumors postmetformin treatment [41] while the
other found no effect [40]. Serum insulin-like growth fac-
tor-1 (IGF-1) and leptin were found to decrease with
metformin treatment in both of these studies [40]. In the
study by Soliman et al., metformin treatment resulted in
decreased phosphorylation of Akt and MAPK in the
malignant endometrium, with no effects on AMPK activa-
tion [40]. Mitsuhashi et al. found that metformin resulted
in decreased phosphorylation of S6 and the extracellular
signal-regulated kinase 1/2 (ERK 1/2) and increased phos-
phorylation of AMPK.
Similar to the other preoperative window studies in
breast and endometrial cancer [18, 40], we found that
metformin significantly decreased phosphorylation of
downstream targets of the mTOR pathway, including
p-Akt, p-S6, and p-4E-BP-1. Metformin was also found
to decrease p-AMPK staining, which was counterintuitive
to what we expected. It is known that metformin exerts
its local antiproliferative effects through activation of
AMPK; and thus, we would have expected an increase in
AMPK phosphorylation instead of a decrease in endome-
trial cancer tumors with metformin treatment. Possible
explanations for this observed finding could be related to
an overall depletion in ATP as a result of metformin
treatment or that metformin may not have direct effects
on the endometrium itself. Controversy surrounds
whether metformin’s antitumorigenic benefits stems from
its indirect effects via decreasing circulating insulin and
glucose levels or its direct effects in tumor cells via AMPK
activation and inhibition of the mTOR pathway. Our
findings for evidence of mTOR pathway inhibition with-
out AMPK activation in endometrial tissues could reflect
a reduction in circulating growth factors such as insulin
and glucose that indirectly leads to decreased activation
of the mTOR pathway. Alternatively, metformin has also
been found to inhibit the mTOR pathway via AMPK-
independent mechanisms through its effects on the Ragu-
lator complex (Rag GTPase) and REDD1 upregulation
[42]. Soliman et al. in their preoperative window study in
endometrial cancer patients found that metformin had no
effect on phophorylated-ACC, a substrate of AMPK [40].
In addition, metformin did not increase AMPK signaling
in obese rat endometrium, despite its robust effects in vi-
tro [43].
Metformin was found to decrease ER expression in the
malignant endometrium but had no effect on progester-
one receptor expression. In endometrial cancer cell lines,
as well as breast cancer animal models [44, 45], metfor-
min has been reported to increase progesterone receptor
expression with little effects on ER expression. However,
Markowska et al. reported in type 1 endometrial cancer
specimens a decrease in ER expression but progesterone
receptor expression, among the tumors of diabetic women
on metformin versus those women using insulin [46].
Metformin has been demonstrated to attenuate estrogen-
stimulated proliferation in the obese rat endometrium
and in normal rat endometrial cell lines [43]. This most
likely occurs via metformin’s inhibitory effects on the
mTOR pathway, regardless of whether this occurs by its
hypothesized indirect or direct effects.
Strengths of our study include the use of a standard
clinical starting dose of metformin that continued until
24 h prior to surgery. The utilization of metabolomic
profiling to assess for metabolic biomarkers of response
to metformin was a novel strategy embedded in this pre-
operative window clinical trial. Limitations of this study
include the absence of a control or placebo arm, the
small sample size, and the lack of posttreatment endo-
metrial tumors on all patients enrolled. In addition,
patients had a relatively short period of exposure to
metformin, although the optimal duration of exposure
to metformin for its potential antitumorigenic benefits is
unknown.
Based on preclinical and epidemiological evidence, clin-
ical trials are emerging for endometrial cancer and hyper-
plasia. Studies that are being conducted include a clinical
trial of single agent metformin for the treatment of endo-
metrial hyperplasia without atypia (NCT01685762), a che-
moprevention study of metformin in obese women
(NCT01697566), a phase 2 trial of metformin in combi-
nation with letrozole/RAD001 in advanced and recurrent
endometrial cancer patients (NCT01797523), and metfor-
min in combination with the levonorgestrel-releasing
intrauterine device in nonsurgical patients with endome-
trial cancer/complex atypical hyperplasia (NCT02035787)
(www.clinicaltrials.gov). Two of these trials are being con-
ducted at our institution, and we plan to further assess
the metabolites associated with response to metformin
treatment in this preoperative window study through
these other ongoing clinical trials. Lastly, the Gynecologic
Oncology Group (GOG) is conducting a randomized,
placebo-controlled phase 2/3 clinical trial of metformin in
combination with paclitaxel/carboplatin versus paclitaxel
and carboplatin alone in women with advanced and
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recurrent endometrial cancer (GOG 286B) (NCT
02065687). This trial is uniquely stratified for obesity and
should help answer the question of whether obesity and
insulin resistance will predict responsiveness to metformin
for cancer treatment, as some of the preclinical studies
suggest [20, 38, 39]. In addition to BMI, other metabolic
characteristics will be followed throughout this trial,
including hip-to-waist ratio and fasting insulin and
glucose levels.
In conclusion, the preclinical, epidemiologic, and clini-
cal data supporting the use of metformin in the preven-
tion and treatment of cancers is building, including that
of endometrial cancer. The association between obesity,
insulin resistance, and increased risk and poor outcomes
in endometrial cancer patients makes metformin an
attractive agent for the prevention and treatment of this
disease. Multiple clinical trials are in progress that will
shed further light on the potential benefits of metformin
in cancer patients, including that of endometrial cancer
patients.
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Additional Supporting Information may be found in the
online version of this article:
Table S1. Serum metabolites significantly altered in res-
ponders and nonresponders to metformin when compar-
ing post- and pretreatment. Metabolomic analysis of
serum indicated significant responses to metformin treat-
ment in non-responders (Non-Res), responders (Res) and
grouped posttreatment (Tx) over pretreatment
(*P < 0.05, #P = 0.1–0.05). Serum was successfully col-
lected pre- and postmetformin treatment on 12/13
responders to metformin treatment and 6/7 nonrespond-
ers to metformin, and these samples were included in this
metabolomic analysis.
Table S2. Lipid metabolites that were altered in the serum
of endometrial cancer patients after treatment with met-
formin. Serum was successfully collected pre- and post-
metformin treatment on 12/13 responders to metformin
treatment and 6/7 nonresponders to metformin, and these
samples were included in this metabolomic analysis.
Table S3. Lipid metabolites that were altered in the
tumors of endometrial cancer patients after treatment
with metformin. Postmetformin tumors were successfully
obtained from 9/13 responders and 3/7 nonresponders.
Table S4. Glycogen metabolites that were altered in the
tumors of endometrial cancer patients after treatment
with metformin. Postmetformin tumors were successfully
obtained from 9/13 responders and 3/7 nonresponders.
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